Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07074977 · ClinicalTrials.gov registry record · Phase 2
Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO)
A Phase 2 study of Chronic Pruritus of Unknown Origin, sponsored by Galderma R&D.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 18
- Study locations
NCT07074977 is a Phase 2 study of Chronic Pruritus of Unknown Origin that is actively recruiting participants, run by Galderma R&D. The registered enrollment target is 50 participants. The trial reports 18 study locations across 14 states.
The verdict
NCT07074977, a Phase 2 study of Chronic Pruritus of Unknown Origin, is actively recruiting participants, sponsored by Galderma R&D.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 18
- Study locations
Study Summary
The primary objective of this study is to assess the PK/PD relationship of nemolizumab in adult participants aged 18 years or above with chronic pruritus of unknown origin (CPUO) during a 16-week treatment period.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG nemolizumab
Study Locations (18)
California
- Galderma Investigational Site (site# 8130) - Los Angeles
- Galderma Investigational Site (#9975) - Sacramento
- Galderma Investigational Site (site# 8021) - San Diego
- Galderma Investigational Site (site# 7075) - San Francisco
Florida
- Galderma Investigational Site (#8295) - Miami
- Galderma Investigational Site (site# 7054) - Tampa
Alabama
- Galderma Investigational Site (site# 8893) - Birmingham
Indiana
- Galderma Investigational Site (site# 8142) - Indianapolis
Michigan
- Galderma Investigational Site (site# 8743) - Ann Arbor
Missouri
- Galderma Investigational Site (site# 8521) - Saint Joseph
Nevada
- Galderma Investigational Site (site# 8108) - Las Vegas
New York
- Galderma Investigational Site (site# 7110) - New City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-10-20 |
| Est. Completion | 2027-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07074977
The ClinicalTrials.gov registry entry for NCT07074977 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Pruritus of Unknown Origin appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07074977 reports 18 study locations spanning 14 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT07074977 about?
NCT07074977 is a clinical study titled "Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO)". The primary objective of this study is to assess the PK/PD relationship of nemolizumab in adult participants aged 18 years or above with chronic pruritus of unknown origin (CPUO) during a 16-week treatment period.
What is the current status of trial NCT07074977?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2025-10-20. Estimated completion is 2027-01.
What conditions does trial NCT07074977 study?
This clinical trial studies the following conditions: Chronic Pruritus of Unknown Origin.
What interventions are being tested in trial NCT07074977?
The interventions under investigation include: Placebo (DRUG), nemolizumab (DRUG).
Who is sponsoring clinical trial NCT07074977?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07074977 being conducted?
This trial has 18 study locations across Alabama, California, Florida, Indiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.